|
On Friday, May 17, 2019, the
Centers for Medicare and Medicaid Services issued Medicaid Drug Rebate
Program (MDRP) manufacturer release #110. The release includes information
for manufacturers regarding treatment of rebates paid to Medicare Advantage
Prescription Drug (MA-PD) plans for Part B drugs when calculating MDRP
pricing metrics, such as Average Manufacturers Price (AMP) and Best Price,
as well as Average Sales Price (ASP); further instructions for
manufacturers that wish to terminate their National Drug Rebate Agreement
(NDRA) to assure prompt receipt by CMS of the termination notice; and
further information regarding new manufacturer requests for an NDRA with
respect to optional and mandatory effective dates for state coverage of new
covered outpatient drugs.
|
No comments:
Post a Comment